{"name":"BioCryst Pharmaceuticals","slug":"biocryst-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"BCX7353 capsules","genericName":"BCX7353 capsules","slug":"bcx7353-capsules","indication":"Hereditary angioedema (HAE) with C1-inhibitor deficiency or dysfunction","status":"phase_3"},{"name":"BCX4161","genericName":"BCX4161","slug":"bcx4161","indication":"Hereditary angioedema","status":"phase_2"},{"name":"BCX7353","genericName":"BCX7353","slug":"bcx7353","indication":"Hereditary angioedema (HAE) with C1-inhibitor deficiency or dysfunction","status":"phase_2"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"BCX4208","genericName":"BCX4208","slug":"bcx4208","indication":"Autoimmune conditions (Phase 2 development)","status":"phase_2"}]}],"pipeline":[{"name":"BCX7353 capsules","genericName":"BCX7353 capsules","slug":"bcx7353-capsules","phase":"phase_3","mechanism":"BCX7353 is a selective inhibitor of plasma kallikrein that reduces bradykinin generation in the contact system pathway.","indications":["Hereditary angioedema (HAE) with C1-inhibitor deficiency or dysfunction"],"catalyst":""},{"name":"BCX4161","genericName":"BCX4161","slug":"bcx4161","phase":"phase_2","mechanism":"BCX4161 is a small molecule inhibitor of the C1 inhibitor of the complement system.","indications":["Hereditary angioedema"],"catalyst":""},{"name":"BCX4208","genericName":"BCX4208","slug":"bcx4208","phase":"phase_2","mechanism":"BCX4208 is a PNP (purine nucleoside phosphorylase) inhibitor that increases deoxyadenosine levels to selectively expand T-regulatory cells and suppress autoreactive immune responses.","indications":["Autoimmune conditions (Phase 2 development)","Inflammatory disorders"],"catalyst":""},{"name":"BCX7353","genericName":"BCX7353","slug":"bcx7353","phase":"phase_2","mechanism":"BCX7353 is a selective inhibitor of plasma kallikrein that reduces bradykinin generation in the contact system pathway.","indications":["Hereditary angioedema (HAE) with C1-inhibitor deficiency or dysfunction","Angioedema prevention and acute attack management"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxQSXIxb01OY1loaWIxUDJRRWZXS2h1Z2lFcXJkX2dTXzdzaU5SLU9xRDdVbVlVNGlxRVd5UG5fcXJyeVNJYks5ZWQ3blQzLXJTUG1KT0lQbXNUczJlMDB6M0ZVdXlIWW0zYlgxalJ2bExxWWJDNHB6dmtJbUlqUkg1ZmFzQldRQ2VyTkw0dmxCME1YbEJyVEtDWFZrdEFLSWUzUVFmY09LZDA3N2dHa3paVUVJVXdfSVNPRWQ5TXNCci0ta3NfNENmd1puU2xuWktFdFBQZVpCU1BVck9oOHpzNlo1TUtVSTMtdzdZaHdxZ244MmdKVlZsU053Q3g4Z2s?oc=5","date":"2026-04-05","type":"pipeline","source":"MSN","summary":"BioCryst stock jumps after hours on big pharma suitor buzz — retail sentiment hits 2026 peak - MSN","headline":"BioCryst stock jumps after hours on big pharma suitor buzz — retail sentiment hits 2026 peak","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxPOGxHd0k5VGJSRnJIeDdQbThZRl9OaExDdlU2RmdhNS1UNGpqUHRqMGM4aEpqdXpUNkRnOHJDSXVUc09aTlBlV0puNHJWcGlMbFR4amhnTkhwMUYxS1ZTMDVPYU9QTU9vMFFBYnpQeEZZWTV5eEtmWW5BNWM5YkM4Y2VmTFh3SnA3MktFQ0MzRFVvQTZMRDlBUV92Ym8tTzNWbUVhUnJoOVhFNlc3alpfOWszNjJ1MGlLenlUSzhPV2ZlNTdfMEx3VG1ENzNhTWM?oc=5","date":"2026-03-19","type":"deal","source":"BioSpace","summary":"Revolution, Ascendis Named Top Buyout Targets as Industry Awaits The Big One - BioSpace","headline":"Revolution, Ascendis Named Top Buyout Targets as Industry Awaits The Big One","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOTkFUZjllaTV0VVVlMkxpRXNpamhHUjJxQm00QzNjWW1vQjdQWHlJLWZVSVItUHd4anZRVDhRZzVDNUZqNFEycDRYOFdYMkxBNkhJdi1PNHltOG1YekxjM3ViZ19SamNjYXF5M2poOXlZNVBrUWVzN2pXM1o3dy1PQmxkdC1UY0E?oc=5","date":"2026-03-10","type":"pipeline","source":"Yahoo Finance","summary":"BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush - Yahoo Finance","headline":"BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPWFhLYlRKOHMwdzNxbkhOMFF5bXlFbmM4eHFMc0VXalhraXIwZmRKT3NkR0NwSWRtS0xCY3dzMjFDamgwSDd4UHl1YUp3LTJPeGhTRXFKOXhRb0U2Y1FFOEtZa0g5Nm51WHlwbW8yeGNxSFUtQW5yTVJPUTNueUV3Vk9WeWVtaTFrQjlMXzVwWWxaRGNOYmtEcmRiWQ?oc=5","date":"2026-02-05","type":"pipeline","source":"Contract Pharma","summary":"ADARx Pharmaceuticals Appoints Donald Fong as CMO - Contract Pharma","headline":"ADARx Pharmaceuticals Appoints Donald Fong as CMO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQQmlFVEdNRkZ0eUM4N01Ba0h2Q1ZDdlNLNVIzMmp0dkpFcGc0cnBiNV8tTGJzU0hld2M3dUpLRnRRUHpwb09ZdkhLdl9IR3RqR3ZBM1RmUHl2QXYwMXloLVJLU0d3T3RFMmpjOWFmeFlkWHhoNWlXUkh2S2NpT2ZRN09MUTNwOW9DVk1zN01TVHJjc3Q0enFndkdYb1kxRGVsTUxLejhzWGRZVEFTVDZiNFVoSURweS1GSHdDd2ExbmlyQTY4S0o0MA?oc=5","date":"2026-01-13","type":"pipeline","source":"Investing.com","summary":"Citizens reiterates Market Outperform rating on BioCryst Pharma stock - Investing.com","headline":"Citizens reiterates Market Outperform rating on BioCryst Pharma stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxQakpINTVaTDBJclNlRzhXZkN0VG4taVEzRTNOWU1STDJZYkFSWWN4S1lpNHExaC11dTVqU1BUQzg3ZFlSYVVORk4tcmFEVW9ibUZlSWRkZ09RQzdQLVQzSFUtUTk4b2EtVF9wd3o2aHljampmY1Utb3BOcmhZNG9RT0FNb2FkRlU0SWItamZwRXZPTDRiYnc0TmJmUjdHTktZdi1RalVzZzU5ZHB3UG5xNzJNQ0FwRlZsdlJweVB6NHBybWgtTXpsdFhla2k0UQ?oc=5","date":"2025-12-15","type":"regulatory","source":"Investing.com","summary":"BioCryst Pharma stock rating reiterated by Citizens on pediatric approval - Investing.com","headline":"BioCryst Pharma stock rating reiterated by Citizens on pediatric approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxQM09xYnJGUGcwSnBVUWVNNlBvMkNheEdjVGJmT01ZelBaY0ZVczlYS1BjSTNxSlVjUDNUMEF0TXJPOEx5cTVOUWotTHVWWUM5WnJpemN2VEtIRHdHcy1pNTNPU08tNm1hWWpnWmpNSW1rcExqTTA0aTF5MTlxRHhpV0RRTURZWnZzVWtVRFV2WnlmR2YxaWdzX1dMNVNNbm1KMy10dS1ic2x2WDdGZmEweHJlREItRFlSZWJka0Vyb0dOUzFHTGo3TXNR?oc=5","date":"2025-12-12","type":"pipeline","source":"Stocktwits","summary":"Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today? - Stocktwits","headline":"Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQNUJXWkFra0NDc05odm1mUk5tcmFGelJ0bmNZUVZJaHhrUndFLWN5R3NadU1oaEM3dUlzT2pTd0pnVnZ5VGFWNlkwc0hZYUlVbERMYkRVaW1YSjJ2ZmFKWTdQdHQ0MjlLS2dwdzYyX2pkMFllTWhiMFhyOTk2MzZITjYxTnhrRUs3S0JyT2JBNFYxMlp4NEdvcTFwU1RfVzJ2bWg5RWE4ZGFJOWJNa2hkYXJFc2JfWVVSaU5zdg?oc=5","date":"2025-10-19","type":"pipeline","source":"MedCity News","summary":"BioCryst’s $700M Astria Acquisition Gives It a Shot to Beat Larger Rivals in Rare Disease HAE - MedCity News","headline":"BioCryst’s $700M Astria Acquisition Gives It a Shot to Beat Larger Rivals in Rare Disease HAE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNR3VNa0FUTzVMWUUtcElYWlc2eGR6aEtJdTVYZFVFeHM0MzhGZzBpMk9iem5HR05qMEFGNGdiczl4TFg5WllMMnNqSTU1Yk5NdjM5RXVCNHh1VVhWZXBsUlRMQndIUXJaT1dBRmJteFJsMHJYWnE2X1JmNlhRZ2lRYjFxV2JWQnBUT1RUR3g3OGNkajdHajlTb1NmQkEzYVFSZ3JMUjRDX196a1psSkVpLXZSSjBnR3Mwem5ZNUFEZG53VTU5a042LTlMMFBQV3VKRm05Z1l3?oc=5","date":"2025-10-15","type":"pipeline","source":"GuruFocus","summary":"BioCryst Pharma (BCRX) Receives Raised Price Target from Cantor Fitzgerald | BCRX Stock News - GuruFocus","headline":"BioCryst Pharma (BCRX) Receives Raised Price Target from Cantor Fitzgerald | BCRX Stock News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNV2NiTzB2blpwSkJjM1FrbUhGcThXUF9rMWVjTFBlc0lYTUVhb2hQb20zUjB1Mkhaa1kzalE4QUU4ckdBa3hwR3duZmIyLVhpTG50djVnUWJGNEhFVTRjZ0o1VzJDdUtPVWNjQnBlU294Q2tpOGR3RXhRSmNzSUxVb2JzNnpoMkZlVVk4SGloaWg0RDFVNnhzTU9tU2N4X3J4bXRoeW15UzFSeXlXX1BMR2V0MmJSR1M1WkstVnJkVl8xdkdaMzBlVC02ZHdXUQ?oc=5","date":"2025-10-14","type":"pipeline","source":"Benzinga","summary":"Why Is BioCryst Pharmaceuticals Stock Trading Lower Today? - BioCryst Pharma (NASDAQ:BCRX) - Benzinga","headline":"Why Is BioCryst Pharmaceuticals Stock Trading Lower Today? - BioCryst Pharma (NASDAQ:BCRX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOS2dhTWJzLUhmZGlwTmU4SmxVY2xDTE9RR201T0hHSk0xU3FNWVEyOVNpTldYSWRiV3JyY21PUVFFd1NpZzFFX2ZfZlZWWVRJUS1qbm1YeDNaVHJjUlNUdG5UTlBsXzhPZ2treXY1ZVZlaUNGTkJNWlVPRmR3TjZFeEpBb0U0aXJrT1h5UGszSkQ3WkVYcndWR3BYa3ZvWjJ0cnZyMEpHNA?oc=5","date":"2025-10-09","type":"regulatory","source":"RTTNews","summary":"BioCryst Pharma Nears Defining FDA Moment For Pediatric HAE Therapy - RTTNews","headline":"BioCryst Pharma Nears Defining FDA Moment For Pediatric HAE Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOcTJ4V2kzQjJtbFg4Q182ZHptVVZkS2hlV2F0cE1BWTF5NktfdGMzZDJ0S2s1dDNVandUeGFfQTZPV1ltRDNKbDk1QWhhNXJGT2FRUjlNOVJEcng3RFJ5NUJtREVtaTNTUjV0dkt2Rlo1RW1tblZNQ2FUekxoSVN0TkFCY0JsTXVUSDRiQm4wMGMtVkJkUm1pLVU2TFkwdHRmSzM4Uzh4NzM5Z1U?oc=5","date":"2025-06-29","type":"deal","source":"MedCity News","summary":"BioCryst Pharma Sells European Business for Rare Disease Drug in $250M Deal - MedCity News","headline":"BioCryst Pharma Sells European Business for Rare Disease Drug in $250M Deal","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":1,"phase_2":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}